Close-up TV News - Prolotheray lecture

Reversing Hypertension

Heavy Metals and all diseases

Close-Up TV News - Dr. Calapai's approach

News 12 Interview: Parkinson’s Disease, Glutathione and Chelation Therapy

News 12 Interview: Platelet-rich plasma therapy

Prolotherapy Interview News 12

News 12 Interview: Diabetes and Weight Loss
Preconceptional paternal exposure to radiation or heavy metals like cadmium can induce cancer in unexposed offspring *

The use of heavy metals like depleted uranium (DU) and tungsten alloy (WA) in military munitions could result in soldiers being wounded with heavy metal shrapnel. The long-term health effects, including carcinogenic and transgenerational effects of chronic exposure to internalized DU or WA, are not fully understood. Currently, no known birth defects have been observed in children from DU-injured fathers. However, it is unknown whether these embedded fragments will affect the long-term health of offspring conceived by these soldiers. Studies have demonstrated that paternal preconceptional exposure to radiation or heavy metals like cadmium can induce cancer in unexposed offspring. To address this question, we investigated the paternal transmission of genetic damage in offspring of male rodents carrying embedded DU fragments using a transgenic mouse model.

This system allows us to assess {lambda}lacI gene mutation frequency in multiple tissues obtained from progeny of exposed fathers by employing a {lambda}lacI shuttle vector carried by cells of a transgenic mouse (Big Blue: strain C57BL/6 hemizygous mice containing 40 copies of a {lambda}lacI shuttle vector per cell). Male rodents were internally exposed to DU or WA (high and low dose) and the mutation frequencies in testes and bone marrow were then measured. Offspring from exposed male parents were genotyped and those positive for the {lambda}lacI gene were assessed for transmission of genetic damage in bone marrow tissue. Data demonstrate that DU exposure (high and low dose) of fathers induced a significant increase in the {lambda}lacI mutation frequency in both testes and bone marrow (10.2- and 6.5 fold elevation respectively).Similar elevations were observed in WA-exposed fathers (7.3- and 4.4 fold elevation).

Offspring from DU-exposed (high dose) male parents also demonstrated a significant increase in the mutation frequency of the {lambda}lacI gene in their bone marrow (9.4-fold elevation). Similarly, a 6.6 fold elevation was measured in offspring from WA-exposed fathers. The mutation frequencies in bone marrow from progeny of males exposed to a lower dose of internalized DU or WA were not significantly different from control (nonsurgical and Tantalum-implanted P1) progeny. The results from this study indicate the possibility of transmission of genomic instability from male parents carrying embedded DU or WA to the somatic cells of their offspring. Further studies are warranted to address these questions.

* Legal Disclaimer: Chelation and Hyperbaric Therapy, Stem Cell Therapy, and other treatments and modalities mentioned or referred to in this web site are medical techniques that may or may not be considered “mainstream”. As with any medical treatment, results will vary among individuals, and there is no implication or guarantee that you will heal or achieve the same outcome as patients herein.

As with any procedure, there could be pain or other substantial risks involved. These concerns should be discussed with your health care provider prior to any treatment so that you have proper informed consent and understand that there are no guarantees to healing.

THE INFORMATION IN THIS WEBSITE IS OFFERED FOR GENERAL EDUCATIONAL PURPOSES ONLY AND DOES NOT IMPLY OR GIVE MEDICAL ADVICE. No Doctor/Patient relationship shall be deemed to have arisen simply by reading the information contained on these pages, and you should consult with your personal physician/care giver regarding your medical treatment before undergoing any sort of treatment or therapy.

Published on 03-02-2009
Authors: Alexandra C. Miller, Rafael Rivas, Robert J. Merlot and Paul Lison
Source: Proc Amer Assoc Cancer Res, Volume 47, 2006